Pharsight

Ryaltris patents expiration

RYALTRIS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937189 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US10758550 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(10 years from now)

US10646500 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(10 years from now)

US10548907 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(10 years from now)

US11400101 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(10 years from now)

US10016443 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine
Sep, 2034

(10 years from now)

US10517880 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US9750754 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US9078923 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US10765686 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US10561672 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US9370483 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US10376526 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
Sep, 2034

(10 years from now)

US11679210 GLENMARK SPECIALTY Dispensing device and pharmaceutical composition for the treatment of rhinitis
Sep, 2038

(14 years from now)

Ryaltris is owned by Glenmark Specialty.

Ryaltris contains Mometasone Furoate; Olopatadine Hydrochloride.

Ryaltris has a total of 14 drug patents out of which 0 drug patents have expired.

Ryaltris was authorised for market use on 13 January, 2022.

Ryaltris is available in spray, metered;nasal dosage forms.

Ryaltris can be used as treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate, treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient, method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway.

The generics of Ryaltris are possible to be released after 03 September, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 13, 2025

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 13 January, 2022

Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient; Treatment of seasonal allergic rhinitis by nas...

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

RYALTRIS family patents

Family Patents